Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Taiwan J Obstet Gynecol ; 60(2): 232-237, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33678321

ABSTRACT

OBJECTIVE: To present the experience on prenatal features of 17q12 microdeletion and microduplication syndromes. MATERIALS AND METHODS: Prenatal chromosomal microarray analysis (CMA) were conducted between January 2015 and December 2018 at a single Chinese tertiary medical centre. Information of cases identified with 17q12 microdeletion or microduplication syndromes were retrospectively collected. Foetal ultrasonographic findings were reviewed, and other information about the gestation week at diagnosis, inheritance and pregnancy outcomes were also included. RESULTS: Ten pregnancies with 17q12 microdeletion and 4 with 17q12 microduplication were identified. The copy number variation (CNV) sizes were 1.39-1.94 Mb in the deleted cases and 1.42-1.48 Mb in the duplicated cases, respectively. All the duplicated and deleted regions included HNF1B and LHX1 genes. Most individuals with 17q12 deletion presented kidney anomalies (9/10), with renal hyperechogenicity being the most common finding (7/10). Fetuses with 17q12 duplication presented a wide phenotypic spectrum, including "double bubble" sign, structural anomalies of the heart and growth anomalies. CONCLUSIONS: Our experience further demonstrated the high correlation between 17q12 microdeletion and renal anomalies especially hyperechogenic kidneys. Structural anomalies of the heart were newly identified phenotypes of 17q12 duplication during prenatal period. Besides, growth anomalies and duodenal atresia might be associated with the duplication.


Subject(s)
Chromosome Deletion , Chromosome Duplication , Chromosomes, Human, Pair 17/genetics , Congenital Abnormalities/embryology , Congenital Abnormalities/genetics , Adult , Congenital Abnormalities/diagnosis , DNA Copy Number Variations , Female , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/embryology , Hepatocyte Nuclear Factor 1-beta/genetics , Humans , Kidney/abnormalities , Kidney/embryology , LIM-Homeodomain Proteins/genetics , Microarray Analysis , Phenotype , Pregnancy , Prenatal Diagnosis , Retrospective Studies , Syndrome , Transcription Factors/genetics
2.
Biochem Biophys Res Commun ; 455(1-2): 90-7, 2014 Dec 05.
Article in English | MEDLINE | ID: mdl-25451272

ABSTRACT

We studied two patients from a nonconsanguineous family with life-long abnormal liver function, hepatomegaly and abnormal fatty acid profiles. Abnormal liver function, hypoglycemia and muscle weakness are observed in various genetic diseases, including medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and glycogen storage diseases. The proband showed increased free fatty acids, mainly C8 and C10, resembling fatty acid oxidation disorder. However, no mutation was found in ACADM and ACADL gene. Sequencing of theamylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) gene showed that both patients were compound heterozygotes for c.118C > T (p.Gln40X) and c.753_756 del CAGA (p.Asp251Glufsx29), whereas their parents were each heterozygous for one of these mutations. The AGL protein was undetectable in EBV-B cells from the two patients. Transcriptome analysis demonstrated a significant different pattern of gene expression in both of patients' cells, including genes involving in the PPAR signaling pathway, fatty acid biosynthesis, lipid synthesis and visceral fat deposition and metabolic syndrome. This unique gene expression pattern is probably due to the absence of AGL, which potentially accounts for the observed clinical phenotypes of hyperlipidemia and hepatocyte steatosis in glycogen storage disease type IIIa.


Subject(s)
Glycogen Debranching Enzyme System/genetics , Glycogen Storage Disease Type III/genetics , Mutation , Acyl-CoA Dehydrogenase/deficiency , Adolescent , Cells, Cultured , Fatty Acids/biosynthesis , Fatty Acids, Unsaturated/biosynthesis , Gene Expression , Glycogen Storage Disease Type III/diagnosis , Glycogen Storage Disease Type III/metabolism , Humans , Lipid Metabolism, Inborn Errors/diagnosis , Male
3.
Gene ; 536(2): 362-5, 2014 Feb 25.
Article in English | MEDLINE | ID: mdl-24355556

ABSTRACT

Glycogen storage disease type Ia (GSD-Ia) is an autosomal recessive genetic disorder resulting in hypoglycemia, hepatomegaly and growth retardation. It is caused by mutations in the G6PC gene encoding Glucose-6-phosphatase. To date, over 80 mutations have been identified in the G6PC gene. Here we reported a novel mutation found in a Chinese patient with abnormal transaminases, hypoglycemia, hepatomegaly and short stature. Direct sequencing of the coding region and splicing-sites in the G6PC gene revealed a novel no-stop mutation, p.*358Yext*43, leading to a 43 amino-acid extension of G6Pase. The expression level of mutant G6Pase transcripts was only 7.8% relative to wild-type transcripts. This mutation was not found in 120 chromosomes from 60 unrelated healthy control subjects using direct sequencing, and was further confirmed by digestion with Rsa I restriction endonuclease. In conclusion, we revealed a novel no-stop mutation in this study which expands the spectrum of mutations in the G6PC gene. The molecular genetic analysis was indispensable to the diagnosis of GSD-Ia for the patient.


Subject(s)
Asian People/genetics , Glucose-6-Phosphatase/genetics , Glycogen Storage Disease Type I/genetics , Mutation/genetics , Amino Acid Sequence , Animals , Base Sequence , COS Cells , Cell Line , Child , Chlorocebus aethiops/genetics , Female , Homozygote , Humans , Molecular Sequence Data , RNA Splicing
4.
Antivir Ther ; 16(2): 141-7, 2011.
Article in English | MEDLINE | ID: mdl-21447862

ABSTRACT

BACKGROUND: Genome-wide association studies have recently shown that the rs12979860 polymorphism in IL28B is associated with the response to chronic hepatitis C treatment. The aim of this study was to investigate whether rs12979860 could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in the Chinese Han population. METHODS: The rs12979860 genotype was detected in 259 individuals infected with HCV by DNA sequencing. Among them, 120 patients were administered complete pegylated interferon-α and ribavirin combination therapy and 92 patients were followed for 24 weeks after the cessation of treatment and were divided into different groups according to outcomes of treatment. RESULTS: The rs12979860 genotype CC was the primary genotype (87.64%, 227/259) and genotype TT was found in only one individual within this cohort. The patients with the rs12979860 genotype CC had higher rates of ETR (P=0.0044) and SVR (P=0.0046) than the patients with N-CC (CT or TT). In multivariate analyses, the rs12979860 genotype CC was associated with a substantial difference in rates of achieving ETR (odds ratio [OR] 8.983, 95% confidence interval [CI] 2.173-37.145; P=0.0024) and SVR (OR 24.298, 95% CI 2.27-259.90; P=0.0083). CONCLUSIONS: This study demonstrated for the first time that the rs12979860 variation in IL28B could be a predictor of ETR and SVR in Chinese Han patients infected with HCV. The high frequency of the rs12979860 genotype CC might explain why the SVR rate is higher than that of the average global population.


Subject(s)
Antiviral Agents/therapeutic use , Asian People/genetics , Genetic Variation , Hepacivirus/drug effects , Hepatitis C/genetics , Interleukins/genetics , Adult , Aged , Antiviral Agents/administration & dosage , China/ethnology , Drug Therapy, Combination , Female , Genotype , Hepatitis C/drug therapy , Hepatitis C/virology , Humans , Interferon-alpha/administration & dosage , Interferon-alpha/therapeutic use , Interferons , Male , Middle Aged , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/therapeutic use , Polymorphism, Genetic , Ribavirin/administration & dosage , Ribavirin/therapeutic use , Treatment Outcome , Young Adult
5.
PLoS One ; 5(12): e14237, 2010 Dec 06.
Article in English | MEDLINE | ID: mdl-21151917

ABSTRACT

BACKGROUND: The hepatitis C virus (HCV) Alternate Reading Frame Protein (ARFP or F protein) presents a double-frame shift product of the HCV core gene. We and others have previously reported that the specific antibodies against the F protein could be raised in the sera of HCV chronically infected patients. However, the specific CD4(+) T cell responses against the F protein during HCV infection and the pathological implications remained unclear. In the current study, we screened the MHC class II-presenting epitopes of the F protein through HLA-transgenic mouse models and eventually validated the specific CD4(+) T cell responses in HCV chronically infected patients. METHODOLOGY: DNA vaccination in HLA-DR1 and-DP4 transgenic mouse models, proliferation assay to test the F protein specific T cell response, genotyping of Chronic HCV patients and testing the F-peptide stimulated T cell response in the peripheral blood mononuclear cell (PBMC) by in vitro expansion and interferon (IFN)- γ intracellular staining. PRINCIPAL FINDINGS: At least three peptides within HCV F protein were identified as HLA-DR or HLA-DP4 presenting epitopes by the proliferation assays in mouse models. Further study with human PBMCs evidenced the specific CD4(+) T cell responses against HCV F protein as well in patients chronically infected with HCV. CONCLUSION: The current study provided the evidence for the first time that HCV F protein could elicit specific CD4(+) T cell response, which may provide an insight into the immunopathogenesis during HCV chronic infection.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Hepacivirus/metabolism , Hepatitis C/virology , Viral Fusion Proteins/metabolism , Amino Acid Sequence , Animals , Epitopes/chemistry , HLA Antigens/metabolism , Humans , Interferon-gamma/metabolism , Leukocytes, Mononuclear/metabolism , Mice , Mice, Transgenic , Molecular Sequence Data , Spleen/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...